GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » Market Cap

AEON Biopharma (AEON Biopharma) Market Cap : $61.03 Mil (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AEON Biopharma's share price for the quarter that ended in Mar. 2024 was $11.6. AEON Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 38.12 Mil. Therefore, AEON Biopharma's market cap for the quarter that ended in Mar. 2024 was $442.20 Mil.

AEON Biopharma's quarterly market cap increased from Sep. 2023 ($208.09 Mil) to Dec. 2023 ($267.55 Mil) and increased from Dec. 2023 ($267.55 Mil) to Mar. 2024 ($442.20 Mil).

AEON Biopharma's annual market cap stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($267.55 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AEON Biopharma's Enterprise Value for Today is $67.89 Mil.


AEON Biopharma Market Cap Historical Data

The historical data trend for AEON Biopharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEON Biopharma Market Cap Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
- - - - 267.55

AEON Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - 208.09 267.55 442.20

Competitive Comparison of AEON Biopharma's Market Cap

For the Biotechnology subindustry, AEON Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEON Biopharma's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Market Cap distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Market Cap falls into.



AEON Biopharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

AEON Biopharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.2*37.1596
=$267.55

AEON Biopharma's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$11.6*38.1203
=$442.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEON Biopharma  (AMEX:AEON) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


AEON Biopharma Market Cap Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


AEON Biopharma (AEON Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4040 MacArthur Boulevard, Suite 260, Newport Beach, CA, USA, 92660
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.
Executives
Strathspey Crown Holdings Group, Llc 10 percent owner 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd 10 percent owner 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson officer: Exec VP, CLO & Corp Secretary 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh officer: Chief Medical Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth director, officer: Chief Executive Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer director C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik 10 percent owner 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds officer: Chief Financial Officer 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano director, 10 percent owner 110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter director C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith officer: Chief Legal Officer&Secretary 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301